Vaccine

Strong and balanced immune responses from a SARS-CoV-2 protein booster with special particles after an mRNA vaccine

Updated

Abstract

The homologous mRNA/LNP regimen induced a strong humoral response with a more balanced IgG1:IgG2c ratio.

  • Heterologous vaccinations may lead to immune responses reflective of the initial vaccine received.
  • Robust cellular responses in heterologous regimens were observed only when primed with mRNA/LNP vaccines.
  • The homologous protein subunit regimen resulted in a dominating IgG1 response with strong CD4T cell activation only.
  • Different vaccination regimens could induce varying immunological profiles, potentially affecting long-term immunity.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Bassel Akache has patent licensed to Glycovax Pharma. Usha D. Hemraz has patent licensed to Glycovax Pharma. Michael J. McCluskie has patent licensed to Glycovax Pharma. Yves Durocher has patent issued to Not applicable. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free